EZH2 Y641F
|
Melanoma
|
EZH2 Y641F
|
Melanoma
|
GSK2816126 Sensitive: D – Preclinical
|
GSK2816126 Sensitive: D – Preclinical
|
EZH2 Y641F
|
Melanoma
|
EZH2 Y641F
|
Melanoma
|
dabrafenib Sensitive: D – Preclinical
|
dabrafenib Sensitive: D – Preclinical
|
EZH2 Y641F
|
Melanoma
|
EZH2 Y641F
|
Melanoma
|
JQEZ5 Sensitive: D – Preclinical
|
JQEZ5 Sensitive: D – Preclinical
|
EZH2 Y641F
|
Melanoma
|
EZH2 Y641F
|
Melanoma
|
UNC1999 Sensitive: D – Preclinical
|
UNC1999 Sensitive: D – Preclinical
|
EZH2 Y641F
|
Melanoma
|
EZH2 Y641F
|
Melanoma
|
dabrafenib + JQEZ5 Sensitive: D – Preclinical
|
dabrafenib + JQEZ5 Sensitive: D – Preclinical
|